JP2008542386A5 - - Google Patents

Download PDF

Info

Publication number
JP2008542386A5
JP2008542386A5 JP2008514814A JP2008514814A JP2008542386A5 JP 2008542386 A5 JP2008542386 A5 JP 2008542386A5 JP 2008514814 A JP2008514814 A JP 2008514814A JP 2008514814 A JP2008514814 A JP 2008514814A JP 2008542386 A5 JP2008542386 A5 JP 2008542386A5
Authority
JP
Japan
Prior art keywords
och
conh
aryl
chco
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008514814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008542386A (ja
JP5253155B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/021142 external-priority patent/WO2006130707A2/en
Publication of JP2008542386A publication Critical patent/JP2008542386A/ja
Publication of JP2008542386A5 publication Critical patent/JP2008542386A5/ja
Application granted granted Critical
Publication of JP5253155B2 publication Critical patent/JP5253155B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008514814A 2005-06-02 2006-06-01 肥満治療に有用なmao−b阻害剤 Expired - Fee Related JP5253155B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68658505P 2005-06-02 2005-06-02
US60/686,585 2005-06-02
PCT/US2006/021142 WO2006130707A2 (en) 2005-06-02 2006-06-01 Mao-b inhibitors useful for treating obesity

Publications (3)

Publication Number Publication Date
JP2008542386A JP2008542386A (ja) 2008-11-27
JP2008542386A5 true JP2008542386A5 (US20040106767A1-20040603-C00005.png) 2012-07-12
JP5253155B2 JP5253155B2 (ja) 2013-07-31

Family

ID=37482280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008514814A Expired - Fee Related JP5253155B2 (ja) 2005-06-02 2006-06-01 肥満治療に有用なmao−b阻害剤

Country Status (10)

Country Link
US (2) US7649115B2 (US20040106767A1-20040603-C00005.png)
EP (1) EP1890690A4 (US20040106767A1-20040603-C00005.png)
JP (1) JP5253155B2 (US20040106767A1-20040603-C00005.png)
CN (1) CN101300006B (US20040106767A1-20040603-C00005.png)
AU (1) AU2006252540B2 (US20040106767A1-20040603-C00005.png)
CA (1) CA2620476A1 (US20040106767A1-20040603-C00005.png)
IL (1) IL187825A (US20040106767A1-20040603-C00005.png)
NZ (1) NZ564130A (US20040106767A1-20040603-C00005.png)
WO (1) WO2006130707A2 (US20040106767A1-20040603-C00005.png)
ZA (1) ZA200800036B (US20040106767A1-20040603-C00005.png)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI361075B (en) * 2007-03-16 2012-04-01 Brion Res Inst Of Taiwan Pharmaceutical composition for inhibiting the syndrome of snore
EP2053033A1 (en) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
IT1392914B1 (it) * 2009-01-22 2012-04-02 Dipharma Francis Srl Procedimento per la preparazione di (r)-n-propargil-1-amminoindano e suoi sali
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
CN107056630B (zh) * 2017-01-23 2020-01-17 合肥工业大学 一种茚满类衍生物及其合成方法和在医药上的用途
BR112020005489A2 (pt) 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
PT3697785T (pt) 2017-10-18 2023-04-03 Jubilant Epipad LLC Compostos de imidazopiridina como inibidores de pad
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
JP7368369B2 (ja) 2017-11-24 2023-10-24 ジュビラント・エピスクライブ・エルエルシー Prmt5阻害剤としてのヘテロ環式化合物
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
US20220409598A1 (en) * 2021-06-21 2022-12-29 Ildong Pharmaceutical Co., Ltd. Method of controlling blood sugar level and treatment of diabetes and related conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) 1965-08-17 Chsx c cech
US3253037A (en) 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1187017A (en) 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
DE69732984T2 (de) * 1996-12-18 2006-02-16 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
EP1078632A1 (en) * 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
DE10142667B4 (de) * 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
CN1606552A (zh) * 2001-12-21 2005-04-13 H.隆德贝克有限公司 氨基茚满衍生物作为5-羟色胺和去甲肾上腺素摄取抑制剂
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
JP2005523289A (ja) 2002-02-27 2005-08-04 テバ ファーマシューティカル インダストリーズ リミティド 脳選択性mao阻害剤としてのプロパルギルアミノインダン誘導体及びプロパルギルアミノテトラリン誘導体
EP2433626B1 (en) * 2003-11-25 2015-11-04 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
WO2005084205A2 (en) * 2004-02-27 2005-09-15 Teva Pharmaceutical Industries, Ltd. Diamino thiazoloindan derivatives and their use
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
JP2008531546A (ja) 2005-02-22 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス

Similar Documents

Publication Publication Date Title
JP2008542386A5 (US20040106767A1-20040603-C00005.png)
JP2010077141A5 (US20040106767A1-20040603-C00005.png)
JP2009504763A5 (US20040106767A1-20040603-C00005.png)
JP2006182786A5 (US20040106767A1-20040603-C00005.png)
JP2010524932A5 (US20040106767A1-20040603-C00005.png)
JP2009529540A5 (US20040106767A1-20040603-C00005.png)
JP2009535358A5 (US20040106767A1-20040603-C00005.png)
JP2007532627A5 (US20040106767A1-20040603-C00005.png)
JP2009530398A5 (US20040106767A1-20040603-C00005.png)
JP2011527332A5 (US20040106767A1-20040603-C00005.png)
JP2014500861A5 (US20040106767A1-20040603-C00005.png)
JP2013512277A5 (US20040106767A1-20040603-C00005.png)
JP2013510120A5 (US20040106767A1-20040603-C00005.png)
JP2010530372A5 (US20040106767A1-20040603-C00005.png)
JP2004516314A5 (US20040106767A1-20040603-C00005.png)
JP2012506872A5 (US20040106767A1-20040603-C00005.png)
JP2012525393A5 (US20040106767A1-20040603-C00005.png)
JP2012533546A5 (US20040106767A1-20040603-C00005.png)
JP2011527334A5 (US20040106767A1-20040603-C00005.png)
JP2007302689A5 (US20040106767A1-20040603-C00005.png)
JP2009502777A5 (US20040106767A1-20040603-C00005.png)
JP2007522135A5 (US20040106767A1-20040603-C00005.png)
JP2020097577A5 (US20040106767A1-20040603-C00005.png)
JP2006507220A5 (US20040106767A1-20040603-C00005.png)
JP2010522710A5 (US20040106767A1-20040603-C00005.png)